Neogen Corp. announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million, subject to customary closing adjustments.
The planned divestiture, which had been previously announced, was part of Neogen’s portfolio review strategy to simplify the business and focus on core strategic markets. The transaction is subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected to be used primarily for debt reduction. The genomics business generated approximately $90 million in sales during fiscal year 2025.
Neogen’s genomics business (GeneSeek®) is a pioneer in advanced DNA testing for livestock and companion animal industries, delivering data-driven insights that contribute to improved animal performance and health and profitability in the beef, dairy, swine and other industries. Through the flagship Igenity® and GGP® portfolio and rapid turnaround times, the business offers returns-focused genomic tools and globally recognized standards in genomic prediction to accelerate herd improvement and enable genomics trait screening. GeneSeek is supported by the Encompass™ platform for genomic data integration and strategic partnerships advancing DNA-backed traceability.
The genomics business serves customers in more than 120 countries through five laboratories in the U.S., Brazil, Australia, China and the U.K. as well as an office location in Canada. The business leverages a comprehensive genotyping platform of fixed array and sequencing technologies, as well as software solutions that empower customers to make informed and data-driven decisions. The business is a leader in U.S. beef and dairy genomics, and its cutting-edge technologies enable highly accurate, scalable genetic testing and deeper insights into animal health, productivity and sustainability.
“This transaction is part of the company’s strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward,” said Mike Nassif, Neogen chief executive officer and president. “Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety. We are committed to a smooth transition for customers, employees and other stakeholders and believe the business is well positioned to thrive under Zoetis’ ownership.”
This acquisition aligns directly with Zoetis’ strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its Precision Animal Health portfolio. By integrating Neogen’s genomic technologies and data solutions, Zoetis is expanding its capabilities to deliver predictive insights, individualized care and greater value to customers across major livestock and companion animal species.
Zoetis expects to complete the acquisition in the second half of calendar year 2026 and is committed to a seamless integration, supporting continuity for colleagues and customers and building on Neogen’s legacy of innovation in genomics.
“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data and technology,” said Jamie Brannan, chief commercial officer at Zoetis. “As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”
